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Abstract
Background: To report on relationships among baseline serum anti-Müllerian hormone (AMH) measurements,
blastocyst development and other selected embryology parameters observed in non-donor oocyte IVF cycles.
Methods: Pre-treatment AMH was measured in patients undergoing IVF (n = 79) and retrospectively correlated to
in vitro embryo development noted during culture.
Results: Mean (+/- SD) age for study patients in this study group was 36.3 ± 4.0 (range = 28-45) yrs, and mean
(+/- SD) terminal serum estradiol during IVF was 5929 +/- 4056 pmol/l. A moderate positive correlation (0.49; 95%
CI 0.31 to 0.65) was noted between basal serum AMH and number of MII oocytes retrieved. Similarly, a moderate
positive correlation (0.44) was observed between serum AMH and number of early cleavage-stage embryos (95% CI
0.24 to 0.61), suggesting a relationship between serum AMH and embryo development in IVF. Of note, serum AMH
levels at baseline were significantly different for patients who did and did not undergo blastocyst transfer (15.6 vs.
10.9 pmol/l; p = 0.029).
Conclusions: While serum AMH has found increasing application as a predictor of ovarian reserve for patients prior
to IVF, its roles to estimate in vitro embryo morphology and potential to advance to blastocyst stage have not
been extensively investigated. These data suggest that baseline serum AMH determinations can help forecast
blastocyst developmental during IVF. Serum AMH measured before treatment may assist patients, clinicians and
embryologists as scheduling of embryo transfer is outlined. Additional studies are needed to confirm these
correlations and to better define the role of baseline serum AMH level in the prediction of blastocyst formation.
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Background
Anti-Müllerian hormone (AMH), a dimeric glycoprotein
member of the transforming growth factor-b superfamily,
is a product of the granulosa compartment involved in
regulation of early ovarian follicular growth and cyclic
follicular selection [1,2]. AMH has a highly conserved
promoter region and plays a crucial role in mammalian
reproduction [3]. Recent data have identified serum
AMH as a useful marker for ovarian reserve, as it corre-
lates with number of primordial follicles and declines
with advanced reproductive age [4]. AMH is favoured as
an ovarian reserve test because of its relative constancy
throughout the menstrual cycle [5,6], and its tendency
to be unchanged despite GnRH-agonist pituitary down-
regulation [7] or pregnancy [8]. These aspects of AMH
have encouraged its use before treatment to elucidate
diminished reserve associated with ovarian ageing [9,10].
However, a less well-studied application for pre-IVF
serum AMH is its ability to forecast the developmental
potential of embryos derived from IVF. If pre-treatment
AMH levels could assist in the choice between d3 vs. d5
transfer, this would better manage patient expectations
and help establish provisional embryo transfer schedules.
By correlating embryo morphology noted during in vitro
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blastocyst transfer in IVF patients, the present investiga-
tion sought to clarify this question.
Methods
Study patients
Between September 2009 - December 2009, serum AMH
levels were measured in patients (n = 79) commencing
non-donor gamete IVF at a single centre. All serum sam-
ples were collected during the early follicular phase (d≤7)
within three months of controlled ovarian hyperstimula-
tion for IVF. Treatment cycles incorporating frozen
embryo transfer were excluded. All patients were in good
general health and had normal pre-treatment laboratory
testing; each patient was assessed by a consultant physi-
cian before IVF and written informed consent was
obtained prior to study enrolment. Normal sperm con-
centration, motility, and morphology was observed for
each male partner in this study group, and sperm DNA
fragmentation analysis confirmed sperm chromatin frag-
mentation was < 25%. While this sample included no
severe male factor cases, a limited number of couples
(n =3 )r e q u e s t e d“upfront ICSI” on an individual basis.
All patients in this study were non-smokers. For females,
baseline (pre-treatment) serum AMH values were corre-
lated with the following intercycle parameters: Female
patient age (yrs), terminal serum E2, total number of
oocytes retrieved, number of metaphase II (MII) oocytes
retrieved, number of early cleavage stage embryos pro-
duced after fertilisation, number of embryos with ≥7 cells
present on d3, and the number of blastocysts that had
developed by d5. Neither basal antral follicle count,
serum d3 FSH, nor ampoules/type of gonadotropins con-
sumed during follicular recruitment were recorded for
analysis, although clinical pregnancy rate was also noted
as a secondary endpoint. Because this was a retrospective
study, institutional review board approval was not
required. For all patients, pituitary downregulation was
achieved with twice-daily 200 mcg intranasal nafarelin
acetate (Synarel
®; Phamacia Ltd., Milton Keynes, UK) fol-
lowed by gonadotropin administration and office moni-
toring as described previously [11].
AMH assay procedure
Each patient provided one specimen by peripheral veni-
puncture which was assayedf o rA M Hi nd u p l i c a t ev i a
MIS/AMH ELISA DSL-10-14400 (Diagnostic Systems
Laboratories, Inc.; Webster, Texas USA). This device
used an enzymatically amplified two-site immunoassay
where standards, controls, and samples were incubated in
microtitration wells coated with anti-AMH antibody.
After incubation and washing, anti-AMH detection anti-
body labeled with biotin was added to each well. Strepta-
vidin horseradish peroxidase (HRP) was added to wells
following a secondary incubation/washing. Tetramethyl-
benzidine (TMB) was introduced after a third incubation
and washing procedure, followed by addition of an acidic
stopping solution. Enzymatic turnover of substrate was
determined by dual wavelength absorbance measurement
at 450 nm and 600-630 nm (measured absorbance is
directly proportional to sample AMH content). Standards
were processed concurrently with experimental samples
to determine serum AMH for each specimen. The mini-
mum detectable level of AMH in serum was 0.04 pmol/
ml, with intra- and interassay coefficients of variation of
< 5% and < 8%, respectively.
Assessment of embryo development
Immediately after retrieval oocyte-cumulus complexes
were placed into Universal IVF medium (MediCult; Jyl-
linge, Denmark), with insemination (including ICSI) also
carried out using this reagent under washed liquid paraffin
oil (MediCult, Denmark). Culture was maintained to d5 in
microdrops of BlastAssist media I and II (MediCult, Den-
mark) under washed paraffin oil in a 5%CO2 + 5%O2
atmosphere at 95% humidity. Embryo development was
observed via multi-port inverted optical microscope fitted
with Hoffman contrast modulation (Nikon TE300; Tokyo,
Japan). Daily assessments of embryos were recorded at
200-400× magnification; d5 blastocysts selected for in
utero transfer featured a well-defined inner cell mass and
highly cellular, expanding trophoectoderm [12].
Statistical analysis
The Mann-Whitney test was used to test differences, as
the outcomes were skewed (non-normal distribution). Dif-
ferences measured at p < 0.05 were considered significant;
differences between groups were reported as pseudome-
dians (i.e., median of differences between samples).
Results
In this study group, median (IQR 25;75) female patient
age was 36.1 (33.7; 39.4) overall; patient ages among
those who did (n = 27) and did not (n = 52) attain clinical
pregnancy after embryo transfer were 34.8 (32.2; 37.7)
and 37.1 (34.2; 40.3), respectively (p = 0.073). No ana-
lysed IVF cycles were complicated by ovarian hypersti-
mulation syndrome and there were no cycle cancellations
during the study interval. As summarised in Table 1, pre-
treatment serum AMH was significantly higher among
patients attaining blastocyst transfer compared to those
who did not (15.6 [10.7;22.9] vs. 10.9 [3.6;19.5]; p =
0.029). Consistent with previous reports [4,5], our data
confirmed the inverse relationship between age and basal
serum AMH (correlation -0.48; 95% CI -0.63 to -0.29).
Figure 1 depicts the relationship between patient age and
capacity for blastocyst transfer. As shown in Figure 2,
median pre-treatment serum AMH levels were
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tocyst transfer and those who did not (15.6 vs. 10.9
pmol/l; p = 0.029 by Mann-Whitney test). While median
patient age was higher among patients who underwent
blastocyst transfer compared to patients who did not,
this difference was not significant (37.3 vs. 35.9; p =
0.509). Moreover, basal serum AMH levels were generally
higher among patients who attained a clinical pregnancy,
but this difference was not significant (16.4 vs. 11.4
pmol/l; p = 0.14 by Mann-Whitney test). In this study
population, the observed clinical pregnancy rate was 27/
79 per embryo transfer (34.2%).
Discussion
This investigation is the first to show a positive, albeit
weak, correlation between baseline serum AMH levels
and subsequent blastocyst development during IVF.
Although serum AMH has found increasing application
as a predictor of ovarian reserve, its role in forecasting in
vitro embryo morphology and developmental potential to
the blastocyst stage is still emerging. For example, Riggs
et al [13] found AMH to be a useful biomarker to predict
low vs. high responders among oocyte donors, but not
predictive of embryo morphology or pregnancy outcome
in the recipient population. Similarly, while an earlier
study reported basal serum AMH as useful in predicting
oocyte number and quality, further cleavage up to the
blastocyst stage was not affected by AMH [14]. In con-
trast, the current investigation suggests that baseline
serum AMH determinations can indeed be extended to
estimate blastocyst developmental potential during IVF.
Table 1 Blastocyst development in vitro compared with basal serum AMH and selected clinical/embryology parameters
among IVF patients (n = 79)
No blastocyst
(n = 46)
Blastocyst
(n = 33)
Difference
(95% CI)
p
1
Serum AMH (pmol/l) 10.9 (3.6, 19.5) 15.6 (10.7, 22.9) 4.9 (0.6 to 8.9) 0.029
Age (yrs) 35.9 (33.5, 39.2) 37.3 (33.7, 40.3) 0.7 (-1.4 to 2.7) 0.509
Terminal E2 (pmol/l) 4084 (2996, 5164) 7282 (3572, 10770) 2335 (-260 to 6361) 0.121
Oocytes retrieved (total n) 7 (4, 17) 10 (7, 13) 3 (1, 5) 0.004
MII oocytes retrieved (n) 5 (3, 8) 9 (6, 12) 3 (2, 5) 0.006
Early cleavage embryos (n) 3.5 (2, 6) 6 (5, 9) 3 (2, 4) 0.002
≥7-cell embryos on d3 (n) 1.5 (0, 3) 2 (1, 4) 1 (0, 2) 0.07
1by Mann-Whitney U test
Notes: All data presented as mean (IQR 25,75); AMH = anti-Müllerian hormone; E2 = estradiol;
MII = metaphase II; d3 = post-fertilisation day three
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Figure 1 Basal AMH and female age. Distribution of serum anti-
Mullerian hormone (AMH) levels as a function of female age among
79 IVF patients (pregnancies shown in red).
IVF patients achieving blastocyst transfer
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Figure 2 Basal AMH and blastocyst development.R e l a t i o n
between serum anti-Mullerian hormone (AMH) levels at baseline
and subsequent potential to undergo blastocyst transfer (+BT; n =
33; no BT = 46 patients). Note: Pregnancies are shown in red.
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cyst transfer was possible represents an unexpected find-
ing from our study, and underscores the limitations of
using patient age alone as a method to predict blastocyst
development.
Clinicians and researchers continue to search for
improved methods to estimate ovarian reserve and pre-
dict reproductive outcome. Serum AMH may help solve
this challenge, as it is maximal in females at puberty but
progressively decays throughout reproductive life [15,16].
Indeed, physiologic menopause or surgical removal of
functional ovaries will render serum AMH essentially
undetectable within days [4,17]. More recently, specific
polymorphisms of the AMH receptor have been impli-
cated as additional modulators of sex-steroid activity
[18]. Early determination of reserve is useful not only
because this information helps guide patient counselling,
but it also assists in calibrating the gonadotropin doses
for IVF patients. Risks of poor follicular recruitment [19]
and ovarian hyperstimulation [20,21] would be mini-
mised by accurate and reliable prediction of ovarian
response in IVF. Since serum AMH levels might help
estimate ovarian response for non-IVF patients as well
[22], this test has emerged as an increasingly important
element of basic fertility assessments. When best to
assess serum AMH has also been studied, but baseline
measurement seems to be the most predictive marker for
ovarian response [23]. Whether or not serum AMH can
be validated as the definitive biophysiologic test to pre-
dict the age of menopause remains the subject of active
study and debate [24,25].
Several limitations of this research should be noted.
First, we did not stratify study subjects by infertility aetiol-
ogy, although evidence suggests that different types of
reproductive pathology might impact serum AMH in dif-
ferent ways. For example, ovarian response to gonadotro-
pins is often attenuated in the setting of endometriosis,
and serum AMH is reduced in fertility patients as a func-
tion of severity of the disease [26]. In contrast, polycystic
o v a r ys y n d r o m e( P C O S )i sa ssociated with abnormally
increased follicular numbers and relatively high serum
AMH. This enhanced AMH production by granulosa cells
in women with PCOS may be a dysfunctional manifesta-
tion of impaired access of FSH to the follicular compart-
ment [27]. This retrospective study did not take these
factors into account. Additionally, we should note that
while a trend of higher median serum AMH levels was
observed among patients who conceived compared to
those who did not attain pregnancy, our study was not
designed to detect this difference.
Conclusions
Although others have focused on d3 serum AMH levels
to predict clinical pregnancy [28], the present study
aimed to assess an important intermediate IVF end-
point–blastocyst development. We confirmed a moder-
ate positive correlation between AMH and total number
of retrieved oocytes, as well as the number of MII
oocytes. Our data from blastocyst culture agree with
and extend previous AMH research, where AMH was
noted to have a highly significant correlation with num-
ber of oocytes retrieved and fertilised where d2 and d3
embryo transfer occurs [29]. This investigation also
found pre-treatment serum AMH to have moderate
positive correlations with development of early cleavage-
stage embryos and embryos with at least 7-cells on d3,
observations generally consistent with previous reports
[29,30]. The observed positive correlation between basal
serum AMH and subsequent blastocyst formation will
require larger sampling to refine the role of AMH in
estimating embryo transfer strategies.
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